Danvers, MA – January 31, 2008 – Cell Signaling Technology, Inc. (CST), a leading provider of antibodies for the research market, announced today that it has entered into an assay development partnership agreement with TTP LabTech Ltd. (TTPLT), a technology leader in the supply of custom automation and laboratory instrumentation for the healthcare, biotech and pharmaceutical sectors. Under the agreement, CST will develop and validate antibodies on TTPLT’s Acumen® Explorer/eX3 microplate cytometric platform. The companies intend to enable a platform solution based on Acumen technology and CST’s extensive collection of validated antibodies for high content cellular analysis of cellular signaling and regulatory post-translational modifications.
CST has proprietary technology and expertise in diverse antibody-based assay technologies. These capabilities will be leveraged to develop and optimize a catalog of high content assays for cellular pathway profiling on TTPLT’s Acumen Explorer/eX3 platform. CST will offer these Acumen high content assays to the drug discovery market as CST products, as well as in profiling services.
“TTPLT is a great partner for CST in the high content analysis (HCA) market; TTPLT’s Acumen cytometric platform performs exceptionally well and we are having great success with antibody validation for Acumen-based HCA assay,” said Christopher Bunker, CST’s Director of Pharma Services. “The objective of the TTPLT – CST partnership is to provide researchers an HCA solution that integrates the high performance Acumen platform with CST’s comprehensive pathway toolbox of high-throughput, information-rich cellular assays; moreover, CST will offer these same assays on the Acumen in our HCA Profiling Service.”
“The Acumen range of products is firmly established for use in high throughput-high content screening. This collaboration is an exciting opportunity for CST and TTPLT to work together to co-develop a new range of applications on the Acumen eX3” said Paul Wylie, TTPLT’s Senior Commercial Scientist. “The combination of TTP LabTech’s expertise in fluorescent detection instrumentation and CST’s high quality antibodies creates an excellent opportunity to influence the future of high content multiplex assay analyses.”
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST has developed and optimized procedures enabling the delivery of high value reagents, immuno-assays and contract services for research and drug development markets focused on cellular phosphorylation and signaling analysis profiles. Information on CST can be obtained at the Company’s website at www.cellsignal.com.
Based near Cambridge, UK, TTP LabTech supplies custom automation and laboratory instrumentation for the healthcare, biotech and pharmaceutical sectors. TTP LabTech’s products are designed to increase efficiency, effectiveness, flexibility or overall capability in key biopharmaceutical research processes including compound storage (comPOUND®), low volume liquid handling (mosquito®) and fluorescence detection (Acumen® fluorescence microplate cytometers). TTP LabTech’s Acumen® eX3 is an ultra high throughput, high content screening system. Triple laser scanning at 405, 488 and 633 nm ensures a wide choice of fluorescent reagents. Acumen eX3 can scan entire wells, offering robust cellular screening data even for rare event assays such as mitotic index or stem cell differentiation. www.ttplabtech.com.